Staphylococcal biofilm: penetration and bioavailability of vancomycin with or without rifampin.
Biofilm
Microscopy
Rifampin
Staphylococcus epidermidis
Vancomycin
Journal
Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
22
03
2022
revised:
14
03
2023
accepted:
25
03
2023
medline:
30
5
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
ppublish
Résumé
We measured antibiotic penetration and bioavailability in staphylococcus biofilms using simulated humanized concentrations of fluorescent vancomycin plus or minus rifampin. Vancomycin percent recovery across biofilm layers was:upper = 46%, middle = 40%, and lower = 33%. Vancomycin plus rifampin was not significantly different (P = 0.65). Addition of rifampin did not improve vancomycin penetration across biofilm layers.
Identifiants
pubmed: 37116243
pii: S0732-8893(23)00057-3
doi: 10.1016/j.diagmicrobio.2023.115947
pii:
doi:
Substances chimiques
Vancomycin
6Q205EH1VU
Rifampin
VJT6J7R4TR
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115947Informations de copyright
Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of competing interest Kerry LaPlante receives research funding from Merck, Pfizer Pharmaceuticals, Shionogi, Paratek, and Entasis. Callan A. Bleick, Emily T. O'Neill, Geoff Williams, Valentin Antoci, and Kathryn E. Daffinee have no relevant financial relationships. Dioscaris Garcia holds equity in BI Medical, LLC.